Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

(2013) S. Verstovsek et al.   HAEMATOLOGICA

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

(2013) Ruben A Mesa et al.   Journal of Hematology & Oncology

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement

(2011) Ruben A. Mesa et al.   CANCER

Therapeutic approaches in myelofibrosis

(2011) Giovanni Barosi et al.   EXPERT OPINION ON PHARMACOTHERAPY

MPN-associated myelofibrosis (MPN-MF)

(2010) R.A. Mesa et al.   LEUKEMIA RESEARCH

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

(2009) P. Guglielmelli et al.   BLOOD

The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

(2009) Ruben A. Mesa et al.   LEUKEMIA RESEARCH

Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy

(2008) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment

(2008) Omar I. Abdel-Wahab et al.   Annual Review of Medicine

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD

Risk factors for leukemic transformation in patients with primary myelofibrosis

(2008) Jocelin Huang et al.   CANCER